To understand the mechanisms underlying the synergistic anti-tumor effects of TRAIL and CD13 inhibition, we further determined whether CD13 inhibitors might regulate the expression of the TRAIL receptors DR4 and DR5, which are essential components in the TRAIL-induced apoptosis pathway20. The gene discussed is TNFRSF10B; the disease is neoplasm.